RNA, U2 small nuclear 13, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU2-13P profile across patient tissues and cancer cell-line models. RNU2-13P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU2-13P is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, RNU2-13P RNA expression shows 9,334 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight LIHC, PRAD, and BRCA as cancer lineages where RNU2-13P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU2-13P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU2-13P survival associations across molecular data types. RNU2-13P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU2-13P RNA expression–survival associations across cancer types. High RNU2-13P expression shows unfavorable associations in LIHC, UVM, BLCA, SKCM, OV and DLBC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU2-13P RNA expression.
This table summarizes RNU2-13P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for RNU2-13P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU2-13P shows higher tumor expression in PRAD and LUAD. The PRAD box plot shows higher RNU2-13P RNA expression in tumor versus normal tissue (log2 FC = +0.432, t-test p = .026).
This table shows molecular features associated with RNU2-13P in patient tissues and cancer cell lines. In patient samples, RNU2-13P shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set.
